Oxygenta Pharma

{
  "main_header": {
    "sid": 798135,
    "name": "Oxygenta Pharma",
    "stock_name": "Oxygenta Pharma",
    "full_name": "Oxygenta Pharmaceutical Ltd",
    "name_url": "stocks-analysis/oxygenta-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "68.00",
    "chg": 2.36,
    "chgp": "3.6%",
    "dir": 1,
    "prev_price": "65.64",
    "mcapval": "251.49 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524636,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE102E01018",
    "curr_date": "Aug 12, 09:58 AM",
    "curr_time": "09:59 AM",
    "last_traded_at": "Aug 12, 09:58 AM IST",
    "bse_nse_vol": "15.11 k",
    "exc_status": "Active",
    "traded_date": "Aug 12, 2026",
    "traded_date_str": "2026 08 12",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/oxygenta-pharma-798135-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-4141446",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/OxygentaPharmac_mojoScore_4141446.png",
        "date": "2026-08-07 10:11:24",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Are Oxygenta Pharmaceutical Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-oxygenta-pharmaceutical-ltd-latest-results-good-or-bad-4124634",
        "imagepath": "",
        "date": "2026-07-28 19:17:34",
        "description": "Oxygenta Pharmaceutical Ltd's latest financial results for Q1 FY27 present a complex picture of operational performance. The company reported net sales of ₹37.00 crores, reflecting a significant year-on-year growth of 144.55% compared to ₹15.13 crores in Q1 FY25. However, this growth was accompanied by a sequential decline of 25.42% from the previous quarter, indicating potential volatility in sales.\n\nThe operating profit, excluding other income, improved to ₹0.55 crores, marking the highest level in the past seven quarters, with an operating margin of 1.49%. This represents a notable recovery from deeply negative margins in prior periods, suggesting some operational efficiencies may be taking hold. However, the margin remains low by industry standards, raising questions about sustainability.\n\nDespite the topline growth, the company continues to face challenges on the bottom line, reporting a net loss of ₹2..."
      },
      {
        "title": "Oxygenta Pharmaceutical Q1 FY27: Revenue Surge Masks Persistent Losses as Turnaround Remains Elusive",
        "link": "https://www.marketsmojo.com/news/result-analysis/oxygenta-pharmaceutical-q1-fy27-revenue-surge-masks-persistent-losses-as-turnaround-remains-elusive-4124383",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/OxygentaPharmac_quaterlyResult_4124383.png",
        "date": "2026-07-28 09:47:46",
        "description": "Oxygenta Pharmaceutical Limited, a micro-cap pharmaceutical company with a market capitalisation of ₹187.00 crores, reported its Q1 FY27 results with a dramatic revenue surge that failed to translate into profitability. The company posted a net loss of ₹2.10 crores for the quarter ended June 2026, representing a marginal improvement from the ₹1.70 crore loss in Q4 FY26 but a significant deterioration from the ₹6.11 crore loss in Q1 FY25. Despite net sales surging 144.55% year-on-year to ₹37.00 crores, the company remains trapped in a loss-making spiral that has persisted across multiple quarters, raising serious questions about operational viability and the sustainability of its business model."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-4122427",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/OxygentaPharmac_mojoScore_4122427.png",
        "date": "2026-07-27 10:10:31",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 July 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "When is the next results date for Oxygenta Pharmaceutical Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-oxygenta-pharmaceutical-ltd-4118333",
        "imagepath": "",
        "date": "2026-07-23 23:17:05",
        "description": "The next results date for Oxygenta Pharmaceutical Ltd is scheduled for 25 July 2026...."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-4104973",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/OxygentaPharmac_mojoScore_4104973.png",
        "date": "2026-07-16 10:10:29",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 July 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-4089434",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/OxygentaPharmac_mojoScore_4089434.png",
        "date": "2026-07-05 10:10:19",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 05 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-4070269",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/OxygentaPharmac_mojoScore_4070269.png",
        "date": "2026-06-24 10:10:45",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 June 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-4048898",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/OxygentaPharmac_mojoScore_4048898.png",
        "date": "2026-06-12 10:10:24",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 June 2026, providing investors with the latest insights into its performance and outlook."
      }
    ],
    "total": 241,
    "sid": "798135",
    "stock_news_url": "https://www.marketsmojo.com/news/oxygenta-pharmaceutical-798135"
  },
  "announcements": [
    {
      "caption": "Newspaper Advertisement",
      "datetime": "31-Jul-2026",
      "details": "Newspaper Advertisement for Notice of AGM scheduled to be held on 21st August 2026.",
      "source": "BSE"
    },
    {
      "caption": "Reg. 34 (1) Annual Report.",
      "datetime": "30-Jul-2026",
      "details": "Submission of 33rd Annual Report for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Intimation Of Book Closure And Cut-Off Date For The 33Rd Annual General Meeting Of Oxygenta Pharmaceutical Limited.",
      "datetime": "30-Jul-2026",
      "details": "Intimation of Book Closure and Cut-off Date for the AGM",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-08-07 10:11:24

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Are Oxygenta Pharmaceutical Ltd latest results good or bad?

2026-07-28 19:17:34

Oxygenta Pharmaceutical Ltd's latest financial results for Q1 FY27 present a complex picture of operational performance. The company reported net sales of ₹37.00 crores, reflecting a significant year-on-year growth of 144.55% compared to ₹15.13 crores in Q1 FY25. However, this growth was accompanied by a sequential decline of 25.42% from the previous quarter, indicating potential volatility in sales. The operating profit, excluding other income, improved to ₹0.55 crores, marking the highest level in the past seven quarters, with an operating margin of 1.49%. This represents a notable recovery from deeply negative margins in prior periods, suggesting some operational efficiencies may be taking hold. However, the margin remains low by industry standards, raising questions about sustainability. Despite the topline growth, the company continues to face challenges on the bottom line, reporting a net loss of ₹2...

Read full news article

Oxygenta Pharmaceutical Q1 FY27: Revenue Surge Masks Persistent Losses as Turnaround Remains Elusive

2026-07-28 09:47:46

Oxygenta Pharmaceutical Limited, a micro-cap pharmaceutical company with a market capitalisation of ₹187.00 crores, reported its Q1 FY27 results with a dramatic revenue surge that failed to translate into profitability. The company posted a net loss of ₹2.10 crores for the quarter ended June 2026, representing a marginal improvement from the ₹1.70 crore loss in Q4 FY26 but a significant deterioration from the ₹6.11 crore loss in Q1 FY25. Despite net sales surging 144.55% year-on-year to ₹37.00 crores, the company remains trapped in a loss-making spiral that has persisted across multiple quarters, raising serious questions about operational viability and the sustainability of its business model.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-07-27 10:10:31

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

When is the next results date for Oxygenta Pharmaceutical Ltd?

2026-07-23 23:17:05

The next results date for Oxygenta Pharmaceutical Ltd is scheduled for 25 July 2026....

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-07-16 10:10:29

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-07-05 10:10:19

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 05 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-06-24 10:10:45

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 June 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-06-12 10:10:24

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 June 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

View All News